1 April 2020 - The April 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The April issue of the Schedule includes several new listings:

• Atezolizumab (Tecentriq) - new strength
• Atezolizumab (Tecentriq) - restriction change
• Binimetinib (Mektovi) - new medicine
• Brivaracetam (Briviact) - new indication
• Emtricitabine with darunavir ethanolate and cobicistat and tenofovir alafenamide fumarate (Symtuza) - new combination product
• Encorafenib (Braftovi) - new indication
• Lenalidomide (Revlimid) - new indication
• Pegfilgrastim (Fulphila) - new biosimilar medicine
• Trastuzumab emtansine (Kadcyla) - new indication
• Trifluridine with tipiracil hydrochloride (Lonsurf) - new indication
• Triglycerides - medium chain (Nutrini Peptosorb Energy) - new formulation
• Tolvaptan (Jinarc) - restriction change

Read Summary of PBS changes